2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-128735
    N-Formylglycine 2491-15-8
    N-Formylglycine is an endogenous metabolite.
    N-Formylglycine
  • HY-128743
    12-Hydroxydodecanoic acid 505-95-3 98.87%
    12-Hydroxydodecanoic acid is an endogenous metabolite.
    12-Hydroxydodecanoic acid
  • HY-128745
    D-​Glucosamic acid 3646-68-2 98.0%
    D-​Glucosamic acid is an endogenous metabolite.
    D-​Glucosamic acid
  • HY-128878
    Dexloxiglumide 119817-90-2 98.25%
    Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases MRP1-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors.
    Dexloxiglumide
  • HY-130012
    CO23 1370363-74-8 98.00%
    CO23 is a selective thyroid hormone receptor (TR) α agonist and used for growth and development regulation.
    CO23
  • HY-132828
    Odatroltide 1639303-73-3
    Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
    Odatroltide
  • HY-135335
    3'-Hydroxy Repaglinide 874908-14-2 98.20%
    3'-Hydroxy Repaglinide is the major CYP2C8 metabolite of Repaglinide (HY-15209). Repaglinide is a carbamoylmethylbenzoic acid (CMBA) derivative that acts on type 2 diabetes.
    3'-Hydroxy Repaglinide
  • HY-138166
    Rosuvastatin lactone 503610-43-3 98.56%
    Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A) (HMG-CoA inhibitor).
    Rosuvastatin lactone
  • HY-13995B
    Sevelamer carbonate 845273-93-0
    Sevelamer carbonate is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer carbonate binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer carbonate binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer carbonate can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes.
    Sevelamer carbonate
  • HY-143210
    Transfectam 124050-77-7 98.0%
    Transfectam is a cationic lipid able to interact with DNA to form complexes that mediate efficient gene transfer into various eukaryotic cells.
    Transfectam
  • HY-145412
    GLP-1 receptor agonist 7 2736447-04-2 98.17%
    GLP-1 receptor agonist 7 (Compound 130b) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC50 of ≤ 0.2 nM. GLP-1 receptor agonist 7 can be used to study diseases related to the GLP-1 receptor (particularly type 2 diabetes).
    GLP-1 receptor agonist 7
  • HY-147623
    GLP-1R agonist 10 2762515-25-1 98.19%
    GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC50 of 0.051 nM.
    GLP-1R agonist 10
  • HY-148505
    5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite) 1197033-17-2 99.17%
    5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is a potent nucleic acid analog. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite blongs to modified antisense oligonucleotide. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite allows the formation of a specific conformation of the furanose ring of the oligonucleotide through the introduction of a cEt modification, enhancing the ability to hybridize to complementary RNA. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is mainly used in the research of regulation of gene expression related to metabolic diseases, cardiovascular diseases, cancers and the development of antisense compounds.
    5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite)
  • HY-148815
    Nampt activator-1 701929-65-9 98.63%
    Nampt activator-1 is a nicotinamide phosphoribosyltransferase (NAMPT) activator, with an EC50 of 3.3~3.7 μM. Nampt activator-1 enhances the enzymatic activity of NAMPT. Nampt activator-1 can be used for research related to metabolic disorders.
    Nampt activator-1
  • HY-149276
    SLC26A3-IN-2 950348-60-4 99.88%
    SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
    SLC26A3-IN-2
  • HY-150618
    PI3Kα-IN-9 2715287-67-3 98.78%
    PI3Kα-IN-9 (compound 27) is a selective, long-acting and oral active PI3Kα inhibitor with IC50 values of 4.4, 128, 146 and 153 nM for PI3Kα, PI3Kγ, PI3Kδ and PI3Kβ, respectively. PI3Kα-IN-9 has antiproliferative activity and induces apoptosis. PI3Kα-IN-9 can be used for cancer research.
    PI3Kα-IN-9
  • HY-153894
    SRX3177 2241237-51-2 ≥98.0%
    SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of <2.5 nM (CDK4), 3.3 nM (CDK6), 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ) , respectively. SRX3177 blocks the interaction between the SARS-CoV-2 E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer.
    SRX3177
  • HY-15409S
    Empagliflozin-d4 2749293-95-4 98.40%
    Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
    Empagliflozin-d4
  • HY-157416
    COP1-ATGL modulator 1 2946701-09-1 99.31%
    COP1-ATGL modulator 1 (86) is an orally active modulator for COP1-ATGL axis. COP1-ATGL modulator 1 (86) could increase ATGL protein expression, reduce ATGL ubiquitination and COP1 autoubiquitination, and diminish lipid accumulation in hepatocytes in the nanomolar range.
    COP1-ATGL modulator 1
  • HY-160618
    11β-HSD2-IN-2 1834601-37-4 99.96%
    11β-HSD2-IN-2 (compound 3) is a selective inhibitor for 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) with an IC50 of 300 nM.
    11β-HSD2-IN-2
Cat. No. Product Name / Synonyms Application Reactivity